Clamp-625 is one of the top 10 brands of Dr. Reddy’s Laboratories, India. Clamp-625 is a combination medicine containing the semisynthetic antibiotic Amoxycillin and the β-lactamase inhibitor, Potassium clavulanate (β-lactamase is a type of enzyme produced by bacteria that resists Amoxycillin action).
Amoxycillin has a bactericidal effect. However, it is susceptible to hydrolysis by β-lactamases. Addition of clavulanic acid extends the antimicrobial spectrum and activity of amoxycillin.
β-lactamase resistance is an increasing problem that results in treatment failure in many common infections. Clamp-625 first overcomes the β-lactamase resistance, and then deals with the bacteria.
Clamp-625 is indicated in various bacterial infections like, Skin and Skin Structure Infections, Urinary Tract Infections, Upper Respiratory Tract Infections, Lower Respiratory Tract Infections.
Clamp-625 is manufactured by Dr. Reddy’s Laboratories (DRL), an Indian multinational pharmaceutical company based in Hyderabad, Telangana, India. The company has a state-of-the-art R&D Centre housing 70 laboratories with over 800 research scientists working on various projects. It works closely with other centres across the UK and the Netherlands, offering wide-ranging access to affordable and innovative medicines – from synthetic organic chemistry to formulations development; from intellectual property management to regulatory science; from polymorphism to bio-pharmaceutics.